IBM Retirement Fund decreased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) by 4.3% during the 1st quarter, HoldingsChannel reports. The fund owned 3,328 shares of the medical equipment provider’s stock after selling 149 shares during the period. IBM Retirement Fund’s holdings in Zimmer Biomet were worth $426,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Amplius Wealth Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $26,000. Widmann Financial Services Inc. acquired a new stake in Zimmer Biomet during the fourth quarter worth $28,000. FSB Premier Wealth Management Inc. acquired a new stake in Zimmer Biomet during the fourth quarter worth $33,000. US Asset Management LLC acquired a new stake in Zimmer Biomet during the first quarter worth $33,000. Finally, Paragon Capital Management Ltd acquired a new stake in Zimmer Biomet during the fourth quarter worth $34,000. Institutional investors and hedge funds own 90.34% of the company’s stock.
Shares of ZBH stock opened at $108.87 on Monday. The stock has a 50-day moving average price of $117.48 and a 200 day moving average price of $121.51. The company has a quick ratio of 0.89, a current ratio of 1.69 and a debt-to-equity ratio of 0.44. The firm has a market cap of $22.82 billion, a price-to-earnings ratio of 105.70, a PEG ratio of 2.61 and a beta of 1.16. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.22 and a 12 month high of $167.59.
Zimmer Biomet (NYSE:ZBH – Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The medical equipment provider reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.21. The firm had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.59 billion. Zimmer Biomet had a return on equity of 12.23% and a net margin of 2.85%. The company’s revenue was up 3.9% on a year-over-year basis. During the same period last year, the company earned $1.71 earnings per share. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 6.72 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Monday, June 27th will be given a $0.24 dividend. The ex-dividend date of this dividend is Friday, June 24th. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. Zimmer Biomet’s payout ratio is 93.20%.
A number of equities research analysts have weighed in on the stock. Truist Financial decreased their price target on shares of Zimmer Biomet from $142.00 to $131.00 in a research note on Wednesday, May 4th. StockNews.com downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Thursday, May 12th. Needham & Company LLC cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Friday, May 27th. Loop Capital cut Zimmer Biomet from a “buy” rating to a “hold” rating and set a $130.00 price objective for the company. in a report on Wednesday, March 2nd. Finally, Stifel Nicolaus lifted their price objective on Zimmer Biomet from $130.00 to $140.00 in a report on Tuesday, May 3rd. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average target price of $141.00.
Zimmer Biomet Profile (Get Rating)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating).
Receive News & Ratings for Zimmer Biomet Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zimmer Biomet and related companies with MarketBeat.com’s FREE daily email newsletter.